NewsBenzingaIGC Pharma Receives Patent From Canadian Intellectual Property Office Covering Composition Of IGC-AD1 Therapy For Agitation In Alzheimer IGC Pharma Receives Patent From Canadian Intellectual Property Office Covering Composition Of IGC-AD1 Therapy For Agitation In Alzheimer Benzinga 2026.11.05 15:21 (GMT+0) Open on Benzinga Other news RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Raises Price Target to $38 Barclays Maintains Overweight on Coca-Cola Europacific, Raises Price Target to $124 Barclays Maintains Overweight on Charles River, Raises Price Target to $375 RBC Capital Downgrades Fidelity National Info to Sector Perform, Lowers Price Target to $37 Keefe, Bruyette & Woods Maintains Outperform on Willis Towers Watson, Raises Price Target to $397 Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy
